vs
Side-by-side financial comparison of OneStream, Inc. (OS) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
OneStream, Inc. is the larger business by last-quarter revenue ($163.7M vs $129.7M, roughly 1.3× Travere Therapeutics, Inc.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs 23.6%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 21.8%).
Blue Stream provides cable television, cable telephone, DVR, and up to 1 GIG Internet speed broadband services to customers in the Florida communities of Coral Springs and Weston.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
OS vs TVTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $163.7M | $129.7M |
| Net Profit | $999.0K | — |
| Gross Margin | 69.8% | 98.0% |
| Operating Margin | -3.2% | -25.0% |
| Net Margin | 0.6% | — |
| Revenue YoY | 23.6% | 73.4% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $163.7M | $129.7M | ||
| Q3 25 | $154.3M | $164.9M | ||
| Q2 25 | $147.6M | $114.4M | ||
| Q1 25 | $136.3M | $81.7M | ||
| Q4 24 | $132.5M | $74.8M | ||
| Q3 24 | $129.1M | $62.9M | ||
| Q2 24 | $117.5M | $54.1M | ||
| Q1 24 | $110.3M | $41.4M |
| Q4 25 | $999.0K | — | ||
| Q3 25 | $-8.8M | $25.7M | ||
| Q2 25 | $-18.4M | $-12.8M | ||
| Q1 25 | $-24.0M | $-41.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-171.9M | $-54.8M | ||
| Q2 24 | $-7.8M | $-70.4M | ||
| Q1 24 | $-5.0M | $-136.1M |
| Q4 25 | 69.8% | 98.0% | ||
| Q3 25 | 68.1% | 99.0% | ||
| Q2 25 | 68.6% | 98.7% | ||
| Q1 25 | 68.0% | 94.3% | ||
| Q4 24 | 66.8% | 96.6% | ||
| Q3 24 | 50.1% | 97.4% | ||
| Q2 24 | 68.5% | 96.2% | ||
| Q1 24 | 69.1% | 96.4% |
| Q4 25 | -3.2% | -25.0% | ||
| Q3 25 | -11.3% | 15.1% | ||
| Q2 25 | -21.8% | -11.1% | ||
| Q1 25 | -29.3% | -52.2% | ||
| Q4 24 | -35.8% | -81.2% | ||
| Q3 24 | -197.6% | -89.3% | ||
| Q2 24 | -9.8% | -125.1% | ||
| Q1 24 | -4.9% | -336.5% |
| Q4 25 | 0.6% | — | ||
| Q3 25 | -5.7% | 15.6% | ||
| Q2 25 | -12.5% | -11.1% | ||
| Q1 25 | -17.6% | -50.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | -133.1% | -87.1% | ||
| Q2 24 | -6.7% | -130.1% | ||
| Q1 24 | -4.5% | -328.9% |
| Q4 25 | — | $0.04 | ||
| Q3 25 | — | $0.28 | ||
| Q2 25 | — | $-0.14 | ||
| Q1 25 | — | $-0.47 | ||
| Q4 24 | — | $-0.71 | ||
| Q3 24 | $-1.06 | $-0.70 | ||
| Q2 24 | — | $-0.91 | ||
| Q1 24 | — | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $693.6M | $93.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $504.7M | $114.8M |
| Total Assets | $1.0B | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $693.6M | $93.0M | ||
| Q3 25 | $653.9M | $110.9M | ||
| Q2 25 | $652.1M | $75.2M | ||
| Q1 25 | $593.9M | $61.9M | ||
| Q4 24 | $544.2M | $58.5M | ||
| Q3 24 | $495.5M | $36.4M | ||
| Q2 24 | $140.5M | $32.3M | ||
| Q1 24 | — | $43.3M |
| Q4 25 | $504.7M | $114.8M | ||
| Q3 25 | $472.1M | $73.6M | ||
| Q2 25 | $458.2M | $32.7M | ||
| Q1 25 | $412.9M | $32.8M | ||
| Q4 24 | $386.2M | $59.1M | ||
| Q3 24 | $458.2M | $-30.5M | ||
| Q2 24 | $97.5M | $15.1M | ||
| Q1 24 | $102.5M | $74.1M |
| Q4 25 | $1.0B | $605.2M | ||
| Q3 25 | $949.4M | $538.6M | ||
| Q2 25 | $910.5M | $555.3M | ||
| Q1 25 | $867.3M | $548.8M | ||
| Q4 24 | $823.2M | $594.1M | ||
| Q3 24 | $750.1M | $504.4M | ||
| Q2 24 | $379.7M | $551.1M | ||
| Q1 24 | — | $663.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $25.8M | $60.7M |
| Free Cash FlowOCF − Capex | $25.6M | — |
| FCF MarginFCF / Revenue | 15.7% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | 25.79× | — |
| TTM Free Cash FlowTrailing 4 quarters | $95.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $25.8M | $60.7M | ||
| Q3 25 | $5.0M | $14.3M | ||
| Q2 25 | $29.7M | $5.0M | ||
| Q1 25 | $36.2M | $-42.2M | ||
| Q4 24 | — | $-35.7M | ||
| Q3 24 | $2.4M | $-42.5M | ||
| Q2 24 | $8.1M | $-40.2M | ||
| Q1 24 | $25.5M | $-119.0M |
| Q4 25 | $25.6M | — | ||
| Q3 25 | $4.8M | $14.2M | ||
| Q2 25 | $29.4M | — | ||
| Q1 25 | $35.8M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.3M | — | ||
| Q2 24 | $7.7M | $-40.3M | ||
| Q1 24 | $24.9M | — |
| Q4 25 | 15.7% | — | ||
| Q3 25 | 3.1% | 8.6% | ||
| Q2 25 | 19.9% | — | ||
| Q1 25 | 26.3% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.0% | — | ||
| Q2 24 | 6.6% | -74.5% | ||
| Q1 24 | 22.5% | — |
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.1% | 0.1% | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.8% | 0.0% | ||
| Q2 24 | 0.3% | 0.2% | ||
| Q1 24 | 0.6% | 0.0% |
| Q4 25 | 25.79× | — | ||
| Q3 25 | — | 0.56× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OS
| Subscription And Circulation | $150.3M | 92% |
| Professional Services And Other | $9.4M | 6% |
| License | $4.0M | 2% |
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
